YOLFTbeta
Biovie Inc

Biovie Inc

BIVI · NASDAQ · Healthcare / Biotechnology

1.13USD-0.06 (-5.04%)

Price History

Full chart

Market Stats

Previous Close1.19
Open1.19
Day Range1.13 – 1.23
52-Week Range0.82 – 3.79
Volume214.74K
Market Cap13.74M
P/E (TTM)0.00
Forward P/E0.00
EPS-3.05
Dividend Yield0.00%
Beta0.74
50-Day Avg1.68
200-Day Avg1.52

About

BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 3 for the treatment of life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism. It also develops Bezisterim, an investigational, novel, orally administered small molecule that is In Phase 3 clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2b clinical trial to treat Parkinson's disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Cuong Viet Do M.B.A.
  • Employees13
  • Headquarters680 W. Nye Lane, Carson City, NV, United States, 89703, USA
  • Websitehttps://bioviepharma.com

Leadership

  • Mr. Cuong Viet Do M.B.A.President, CEO & Director · b. 1966
  • Ms. Joanne Wendy Kim CPACFO, Treasurer & Corporate Secretary · b. 1956
  • Dr. Joseph M. Palumbo M.D.Executive VP of R&D and Chief Medical Officer · b. 1961
  • Mr. Clarence N. AhlemSenior Vice President of Operations · b. 1956
  • Dr. Penelope Markham Ph.D.Senior Vice President of Liver Disease & Long COVID Programs · b. 1966
  • Ms. Denise SmithSenior Vice President of Manufacturing & Development
  • Dr. Christopher L. Reading Ph.D.Senior Vice President of Alzheimer's Disease Program · b. 1948
  • Mr. David MorseSenior VP & Chief Regulatory Officer

Financials

Income Statement

Currency: USD2013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Revenue-0000000000000
Cost of Revenue-0051.04K229.38K229.38K229.38K229.38K229.38K237.42K266.84K229.38K229.38K-
Gross Profit-00-51.04K-229.00K-229.00K-229.00K-229.00K-229.38K-237.42K-266.84K-229.38K-229.38K-
Operating Expense-322.38K233.38K380.99K1.32M2.14M2.27M2.46M137.82M27.02M44.81M31.95M17.84M-
Operating Income-70.06K-322.38K-233.38K-432.03K-1.55M-2.37M-2.50M-2.69M-138.05M-27.25M-45.08M-32.18M-18.07M-22.65M
EBITDA20-321.90K-233.01K-380.81K-1.32M-2.14M-2.27M-2.46M-129.46M-23.69M-45.73M-29.00M-16.98M-21.88M
Net Income-70.04K-321.90K-233.01K-431.92K-1.33M-2.41M-2.44M-16.68M-130.25M-26.08M-50.26M-32.12M-17.54M-22.07M
R&D-49.42K4.20K37.90K466.35K370.85K1.01M1.15M133.19M17.26M33.30M23.10M9.27M13.96M
Interest Expense-48936981222.94K40.96K2734.77M559.46K2.16M4.30M2.89M332.72K17.90K

Balance Sheet

Currency: USD2013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Assets505.70K332.86K269.48K2.72M2.36M2.18M2.57M2.08M6.05M20.11M35.10M25.21M21.56M14.25T
Total Liabilities15.00K161.47K323.60K803.25K1.21M2.06M443.48K23.58M996.37K16.44M19.76M9.70M2.55M3.98T
Total Equity490.70K171.39K-54.12K1.92M1.16M111.20K2.13M-21.50M5.05M3.67M15.34M15.51M19.01M10.27T
Cash505.70K332.86K267.48K123.76K5.14K45.80K339.92K37.20K4.51M18.64M19.46M23.84M17.54M8.98T
Total Debt---10.00K35.00K825.92K-911.04K-12.26M14.42M6.11M349.89K275.43B
Net Debt-505.70K-332.86K-267.48K-113.76K29.86K780.12K-339.92K873.85K-4.51M-6.38M-5.04M-17.73M-17.19M-8.70T

Cash Flow

Currency: USD2013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Operating Cash Flow-10.04K-172.83K-65.38K-163.63K-623.62K-621.34K-2.50M-1.63M-10.45M-18.99M-40.25M-27.95M-19.03M-19.02B
Investing Cash Flow-9.91K9.91K9.91K000-14.30M-14.30M-14.30M-14.30M14.53M--
Financing Cash Flow2.03M-5-5-5505.00K662.00K2.80M1.33M14.93M33.12M55.37M17.80M12.73M10.46B
Capital Expenditure00000000300450
Free Cash Flow-10.04K-172.83K-65.38K-163.63K-623.62K-621.34K-2.50M-1.63M-10.45M-18.99M-40.25M-27.95M-19.03M-19.02B
Dividends Paid--000048.66K17.10M53.60M--886.42K369.46B-
FCF to OCF100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%
Dividend Paid to FCF--0.00%0.00%0.00%0.00%-1.95%-1050.16%-512.75%---3.17%-1941976.45%-

Earnings

Report DateSep 30, 2013Dec 31, 2013Mar 31, 2014Jun 30, 2014Sep 30, 2014Dec 31, 2014Mar 31, 2015Jun 30, 2015Sep 30, 2015Dec 31, 2015Mar 31, 2016Jun 30, 2016Sep 30, 2016Dec 31, 2016Mar 31, 2017Jun 30, 2017Sep 30, 2017Dec 31, 2017Mar 31, 2018Jun 30, 2018Sep 30, 2018Dec 31, 2018Mar 31, 2019Jun 30, 2019Sep 27, 2019Nov 19, 2019Feb 13, 2020May 13, 2020Aug 6, 2020Nov 5, 2020Jan 29, 2021May 10, 2021Aug 30, 2021Nov 10, 2021Feb 8, 2022May 11, 2022Sep 27, 2022Nov 4, 2022Feb 10, 2023May 12, 2023Aug 16, 2023Nov 8, 2023Feb 13, 2024May 14, 2024Sep 30, 2024Nov 6, 2024Feb 11, 2025May 12, 2025Aug 15, 2025Nov 10, 2025Feb 25, 2026Jun 3, 2026Aug 12, 2026Nov 9, 2026
EPS Estimate0.000.000.000.00---------------------------12.00-23.00-232.00-0.23-41.00-71.00-0.37-28.50-25.25-35.50-40.00-31.00-27.50-25.00-0.15-0.27-16.00-3.20-3.60-0.79---0.52-
EPS Actual-0.08-0.07-0.07-0.25-0.08-0.10-0.07-0.08-0.08-0.07-0.08-0.39-0.50-0.51-0.24-0.60-0.89-0.66-0.89-0.73-0.20-0.20-0.34-0.25-0.25-5.061.29-0.07-3.68-3.28-22.00-22.00-1018.77-0.23-22.00-28.00-0.33-38.00-50.00-43.00-23.00-29.00-22.00-20.00-0.80-0.70-4.60-1.50-11.05-0.98-0.77-0.70-0.70-
Surprise-------------------------------83.33%4.35%-339.13%0.00%46.34%60.56%10.81%-33.33%-98.02%-21.13%42.50%6.45%20.00%20.00%-432.13%-159.15%71.25%53.13%-206.94%-24.05%---34.62%-
Timing----------------------------After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours---After-hours

Key Statistics & Ratios

Market Cap13.74M
Enterprise Value5.25M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book1.36
EPS-3.05
Book Value1.36
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-22.47M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-150.76%
Return on Assets-79.06%
Shares Outstanding8.53M
Shares Float7.48M
Beta0.74
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 1 analystsTarget 5.26
  • Strong Buy
    1

Ownership Breakdown

Institutions
22.24%
Insiders
0.53%
Retail / Other
77.23%

Top Institutional Holders

  • Diametric Capital, LP
    370.00K4.38%
  • Citadel Advisors Llc
    95.95K1.14%
  • Springbok Capital Management, LLC
    92.06K1.09%
  • Geode Capital Management, LLC
    84.20K1.00%
  • Vanguard Capital Management, LLC
    84.07K0.99%
  • Morgan Stanley - Brokerage Accounts
    75.22K0.89%
  • Philadelphia Trust Co
    75.01K0.89%
  • Renaissance Technologies Corp
    67.92K0.80%
  • Vanguard Fiduciary Trust Co
    37.56K0.44%
  • HRT FINANCIAL LLC
    23.48K0.28%
  • Jane Street Group LLC
    22.79K0.27%
  • XTX Topco Ltd
    21.23K0.25%
  • Northern Trust Corp
    14.19K0.17%
  • Caprock Group Inc
    11.30K0.13%
  • Tower Research Capital LLC
    7.54K0.09%
  • Hanson Mcclain Inc
    5.60K0.07%

Top Fund Holders

  • Fidelity Extended Market Index
    38.70K0.51%
  • Fidelity Series Total Market Index
    10.90K0.14%
  • Belfund SICAV Belinvest Equity A USD Acc
    10.00K0.13%
  • Fidelity Nasdaq Composite Index
    7.98K0.11%

Stock Splits

  • Jul 7, 20251:10
  • Aug 6, 20241:10